MUNDIBIOPHARMA LIMITED

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 102

Reporting scope

Standalone (parent only)

Auditor

Ernst and Young LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“Management have conducted a review of the business, which includes preparing forecasts for the period to 31 August 2026 that indicate the Company will continue to make profits and have sufficient cash over this period to meet liabilities as they fall due under the new model. Consequently, the directors believe the Company is well positioned to manage its business risks under the new model. Accordingly, the directors have a reasonable expectation that the Company has adequate resources to continue in operational existence for a period to 31 August 2026 and, thus, they continue to adopt the going concern basis of accounting in preparing the annual financial statements.”

Significant events

• “During the year, the Company transitioned its principal activity from the direct purchase and supply of pharmaceutical products, as well as their management and marketing, to a new operating model. In March 2024, the Company novated its supply agreements with customers to an independent associated company.”
• “On January 31, 2024 the Company sold its Consumer Health businesses to iNova Pharmaceuticals (Singapore) Pte Limited (iNova) for which the Company received a consideration of USD 4,749,745, subject to escrow arrangements.”
• “The Company declared an interim preference share dividend of €45,350,245, being the accrued and unpaid preference share dividend... offset against certain interest and loan receivables... a full offset against the loan of €17,687,838 and a partial offset of £19,826,257 against the loan of £43,500,000.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

4

last 12 months

Capital events

1

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  -67.6%

  £209,033,952 → £67,810,842

• Cash

  -71.8%

  £45,754,385 → £12,894,405

• Net assets

  +10.3%

  £93,083,416 → £102,628,254

• Employees

  -37.5%

  8 → 5

• Operating profit

  +3.4%

  £17,009,689 → £17,591,273

• Profit before tax

  +12.1%

  £12,919,677 → £14,478,000

• Wages

  -70.2%

  £2,928,797 → £871,837

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers